Table 1. Comparison of clinicopathological variables according to MHC-II expression in tumor cells.

	MHC-II expression
	No (n = 479)	Low* (n = 86)	High* (n = 116)	p value
Histological grade				0.041
1	0	0	0 (0.0%)
2	21 (18.1%)	14 (16.3%)	126 (26.3%)
3	95 (81.9%)	72 (83.7%)	353 (73.7%)
Pathologic T stage				0.074
1	213 (44.5%)	45 (52.3%)	41 (35.3%)
2	243 (50.7%)	40 (46.5%)	73 (62.9%)
3	22 (4.6%)	1 (1.2%)	2 (1.7%)
4	1 (0.2%)	0	0
Lymph node metastasis				0.726
Negative	332 (69.3%)	57 (66.3%)	83 (71.6%)
Positive	147 (30.7%)	29 (33.7%)	33 (28.4%)
Lymphovascular invasion				0.042
Negative	355 (74.1%)	69 (80.2%)	98 (84.5%)
Positive	124 (25.9%)	17 (19.8%)	18 (15.5%)
TILs (%)				<0.001
≤ 10	144 (30.1%)	13 (15.1%)	8 (6.9%)
20–30	118 (24.6%)	16 (18.6%)	20 (17.2%)
40–60	95 (19.8%)	19 (22.1%)	34 (29.3%)
>60	122 (25.5%)	38 (44.2%)	54 (46.6%)
Peritumoral lymphocytes (Klintrup criteria)				<0.001
0	40 (8.4%)	2 (2.3%)	0 (0.0%)
1	194 (40.5%)	21 (24.4%)	21 (18.1%)
2	184 (38.4%)	45 (52.3%)	57 (49.1%)
3	61 (12.7%)	18 (20.9%)	38 (32.8%)
TLS adjacent to the invasive area				<0.001
No	50 (10.4%)	4 (4.7%)	1 (0.9%)
Mild	85 (17.7%)	12 (14.1%)	12 (10.3%)
Moderate	173 (36.1%)	36 (41.9%)	42 (36.2%)
Severe	171 (35.7%)	34 (39.5%)	61 (52.6%)
MHC class I expression				<0.001
Low	271 (58.0%)	33 (38.4%)	11 (9.5%)
High	196 (42.0%)	53 (61.6%)	105 (90.5%)
PD-L1 expression				<0.001
Negative	440 (96.7%)	74 (87.1%)	83 (71.6%)
Positive (any)	15 (3.3%)	11 (12.9%)	33 (28.4%)
MxA expression				<0.001
Low	321 (67.9%)	48 (55.8%)	50 (43.1%)
High	152 (32.1%)	38 (44.2%)	66 (56.9%)
PKR expression				0.008
Low	256 (54.6%)	37 (43.0%)	47 (40.5%)
High	213 (45.4%)	49 (57.0%)	69 (59.5%)

*The expression of MHC-II molecules was dichotomized into low and high groups using the mean of the immunoreactive score, 27.2; MxA, myxovirus resistance A; PKR, double-stranded RNA-activated protein kinase; TILs, tumor infiltrating lymphocytes; TLS, tertiary lymphoid structure.